Veru Inc.
NASDAQVERU reported fiscal Q2 2026 results today — and the numbers landed well ahead of a deeply pessimistic consensus. The headline fact is a significant earnings beat. Veru posted Q2 EPS of -$0.12, against an estimate of -$0.28. That is a 57% beat on the loss estimate, a meaningful outperformance for a clinical-stage biopharma where the Street had priced in considerably more cash burn…
Snapshot as of 19 Oct 2026
VERU reported fiscal Q2 2026 results today — and the numbers landed well ahead of a deeply pessimistic consensus. The headline fact is a significant earnings beat. Veru posted Q2 EPS of -$0.12, against an estimate of…
Veru Inc. heads into its May 12 quarterly report carrying two distinct stories: a quiet but tightening short position and a freshly filed shelf offering that puts dilution risk squarely on the table. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VERU — free to start on ORTEX.
Sign up for free →Open VERU on ORTEX